Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in refractory IgA nephropathy
NCT05596708Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Mar 2023
- Primary completion
- Jun 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of telitacicept in IgA nephropathy (IgAN), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05596708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05596708.